Quality assurance initiative for systemic treatment in metastatic colorectal cancer

• Conditions: C18; C19; C20; Malignant neoplasm of colon; Malignant neoplasm of rectosigmoid junction; Malignant neoplasm of rectum

• Registration Number: DRKS00033377
• Lead Sponsor: Charite Berlin - Medizinischen Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie (CCM)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-04-09
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 2100

Inclusion Criteria

Diagnosis of mCRC with primarily non-resectable metastases in QIII/23 and QIV/23 and 1st line systemic treatment or 2nd line systemic treatment therapy in the metastatic setting

Exclusion Criteria

Patients with non-metastatic disease
Patients with only primarily resectable metastases
Patients are not suitable for systemic therapy due to reduced general condition or concomitant diseases

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Implementation of the guideline recommendations in routine treatment

Secondary Outcome Measures

Name	Time	Method
The demographic and clinical characteristics of patients in first- and second-line therapy<br>The establishment of liquid biopsy in clinical routine